CN103930439A - 基因工程生长因子变异体 - Google Patents

基因工程生长因子变异体 Download PDF

Info

Publication number
CN103930439A
CN103930439A CN201280034119.XA CN201280034119A CN103930439A CN 103930439 A CN103930439 A CN 103930439A CN 201280034119 A CN201280034119 A CN 201280034119A CN 103930439 A CN103930439 A CN 103930439A
Authority
CN
China
Prior art keywords
protein
cell
noc
dimer
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280034119.XA
Other languages
English (en)
Chinese (zh)
Inventor
辛西娅·巴姆达德
贝努瓦·J·斯马格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minerva Biotechnologies Corp
Original Assignee
Minerva Biotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Biotechnologies Corp filed Critical Minerva Biotechnologies Corp
Priority to CN202010915430.1A priority Critical patent/CN112028985A/zh
Publication of CN103930439A publication Critical patent/CN103930439A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
CN201280034119.XA 2011-05-09 2012-05-08 基因工程生长因子变异体 Pending CN103930439A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010915430.1A CN112028985A (zh) 2011-05-09 2012-05-08 基因工程生长因子变异体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161484052P 2011-05-09 2011-05-09
US61/484,052 2011-05-09
PCT/US2012/036975 WO2012154759A2 (en) 2011-05-09 2012-05-08 Genetically engineered growth factor variants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010915430.1A Division CN112028985A (zh) 2011-05-09 2012-05-08 基因工程生长因子变异体

Publications (1)

Publication Number Publication Date
CN103930439A true CN103930439A (zh) 2014-07-16

Family

ID=47139949

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280034119.XA Pending CN103930439A (zh) 2011-05-09 2012-05-08 基因工程生长因子变异体
CN202010915430.1A Pending CN112028985A (zh) 2011-05-09 2012-05-08 基因工程生长因子变异体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010915430.1A Pending CN112028985A (zh) 2011-05-09 2012-05-08 基因工程生长因子变异体

Country Status (8)

Country Link
US (3) US20140065113A1 (https=)
EP (1) EP2707021B1 (https=)
JP (5) JP2014517690A (https=)
CN (2) CN103930439A (https=)
AU (1) AU2012253652B2 (https=)
CA (1) CA2835453A1 (https=)
IL (1) IL229316B (https=)
WO (1) WO2012154759A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107076729A (zh) * 2014-10-16 2017-08-18 康希尔公司 变异体调用器

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2686418A4 (en) 2011-03-17 2015-04-22 Minerva Biotechnologies Corp METHOD FOR THE PRODUCTION OF PLURIPOTENTAL STEM CELLS
WO2012154759A2 (en) * 2011-05-09 2012-11-15 Minerva Biotechnologies Corporation Genetically engineered growth factor variants
CA2901893C (en) * 2013-02-20 2022-08-30 Minerva Biotechnologies Corporation Nme inhibitors and methods of using nme inhibitors
CA3183682A1 (en) 2020-06-26 2021-12-30 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis
US12144827B2 (en) 2021-02-25 2024-11-19 Lyell Immunopharma, Inc. ROR1 targeting chimeric antigen receptor
CN119317447A (zh) 2022-04-12 2025-01-14 米纳瓦生物技术公司 抗可变muc1*抗体及其用途
CN117736272B (zh) * 2024-02-19 2024-04-30 四川省医学科学院·四川省人民医院 一种具有促成骨功能的生物活性多肽

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020169290A1 (en) * 2000-11-02 2002-11-14 Claus Bornaes New multimeric interferon beta polypeptides
US20060228357A1 (en) * 2005-04-06 2006-10-12 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US20070009918A1 (en) * 1996-04-23 2007-01-11 President And Fellows Of Harvard College Methods and compositions for regulating T cell subsets by modulating transcription factor activity
US20090075926A1 (en) * 2006-12-06 2009-03-19 Bamdad Cynthia C Method for identifying and manipulating cells
US20090175867A1 (en) * 2006-06-12 2009-07-09 Trubion Pharmaceuticals, Inc. Single-Chain Multivalent Binding Proteins with Effector Function
US20100093092A1 (en) * 2008-10-09 2010-04-15 Bamdad Cynthia C Method for inducing pluripotency in cells

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69033810T2 (de) * 1989-10-18 2002-03-28 The Government Of The United States Of America, As Represented By The Secretary National Institute Of Health Herstellung und verwendung des menschlichen nm23-h2-proteins und dagegen gerichtete antikörper
US20050112607A1 (en) * 1999-01-23 2005-05-26 Bamdad Cynthia C. Rapid and sensitive detection of protein aggregation
US7754855B1 (en) * 1999-07-13 2010-07-13 Bolder Biotechnology, Inc. Immunoglobulin fusion proteins
MXPA02001417A (es) * 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
WO2002036626A1 (en) * 2000-11-02 2002-05-10 Maxygen Aps Single-chain multimeric polypeptides
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
EP1397484A4 (en) * 2001-03-27 2005-05-25 Massachusetts Inst Technology METHODS AND PRODUCTS ASSOCIATED WITH FGF DIMERIZATION
EP1353182A3 (en) * 2002-04-12 2004-02-04 Smithkline Beecham Corporation Method of predicting cell-based assay results using binding profiles
AU2003268345A1 (en) * 2002-09-24 2004-04-19 The Burnham Institute Novel agents that modulate eph receptor activity
NZ544924A (en) * 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
US20050054752A1 (en) * 2003-09-08 2005-03-10 O'brien John P. Peptide-based diblock and triblock dispersants and diblock polymers
BRPI0507174A (pt) * 2004-01-28 2008-04-01 Syntonix Pharmaceuticals Inc proteìnas de fusão hormÈnio-fc (fsh-fc) heterodiméricas estimuladoras de folìculo para o tratamento da infertilidade
NZ590667A (en) * 2008-07-02 2013-01-25 Emergent Product Dev Seattle Tgf-b antagonist multi-target binding proteins
MX2011013385A (es) * 2009-06-11 2012-05-29 Minerva Biotechnologies Corp Metodos para cultivar celulas madre y celulas progenitoras.
WO2011103049A2 (en) * 2010-02-16 2011-08-25 Immune Disease Institute, Inc. Method for screening receptors/ligands interactions
EP2686418A4 (en) * 2011-03-17 2015-04-22 Minerva Biotechnologies Corp METHOD FOR THE PRODUCTION OF PLURIPOTENTAL STEM CELLS
WO2012154759A2 (en) * 2011-05-09 2012-11-15 Minerva Biotechnologies Corporation Genetically engineered growth factor variants

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070009918A1 (en) * 1996-04-23 2007-01-11 President And Fellows Of Harvard College Methods and compositions for regulating T cell subsets by modulating transcription factor activity
US20020169290A1 (en) * 2000-11-02 2002-11-14 Claus Bornaes New multimeric interferon beta polypeptides
US20060228357A1 (en) * 2005-04-06 2006-10-12 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US20090175867A1 (en) * 2006-06-12 2009-07-09 Trubion Pharmaceuticals, Inc. Single-Chain Multivalent Binding Proteins with Effector Function
US20090075926A1 (en) * 2006-12-06 2009-03-19 Bamdad Cynthia C Method for identifying and manipulating cells
US20100093092A1 (en) * 2008-10-09 2010-04-15 Bamdad Cynthia C Method for inducing pluripotency in cells

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107076729A (zh) * 2014-10-16 2017-08-18 康希尔公司 变异体调用器

Also Published As

Publication number Publication date
AU2012253652A1 (en) 2013-11-28
IL229316A0 (en) 2014-01-30
EP2707021B1 (en) 2024-02-21
WO2012154759A3 (en) 2014-05-01
JP2024056702A (ja) 2024-04-23
US20200062812A1 (en) 2020-02-27
US20240294590A1 (en) 2024-09-05
JP6717725B2 (ja) 2020-07-01
US20140065113A1 (en) 2014-03-06
CA2835453A1 (en) 2012-11-15
EP2707021A2 (en) 2014-03-19
EP2707021A4 (en) 2015-08-05
IL229316B (en) 2020-02-27
JP2014517690A (ja) 2014-07-24
AU2012253652B2 (en) 2017-07-06
JP2017061471A (ja) 2017-03-30
WO2012154759A2 (en) 2012-11-15
JP2020039359A (ja) 2020-03-19
EP2707021C0 (en) 2024-02-21
JP2022031824A (ja) 2022-02-22
CN112028985A (zh) 2020-12-04

Similar Documents

Publication Publication Date Title
US20240294590A1 (en) Nucleic acid encoding genetically engineered growth factor variants
CN113621075B (zh) SIRP-α变体构建体及其用途
JP6901834B2 (ja) Ｓｉｒｐ−アルファ変異体構築物及びその使用
JP6783797B2 (ja) 抗がん融合ポリペプチド
US7087411B2 (en) Fusion protein capable of binding VEGF
JP2022046544A (ja) ｓｙｎＴａｃポリペプチド及びその使用
JP6809789B2 (ja) 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤
JP2023082052A (ja) キメラ抗原受容体およびその使用
CN106255699B (zh) 细胞穿透肽和使用其输送生物活性物质的方法
US6800286B1 (en) Chimeric fibroblast growth factor proteins, nucleic acid molecules, and uses thereof
JP2020506701A (ja) 組織特異的Ｗｎｔシグナル増強分子およびその使用
KR20150093768A (ko) 단백질 발현 증진 폴리펩타이드
CZ2001643A3 (cs) Exprese a export inhibitorů angiogeneze ve formě imunofúzinů
JP6499080B2 (ja) 安定化されたインスリン様成長因子ポリペプチド
CN110114371A (zh) 嵌合抗原受体
JP2017505141A (ja) 長時間作用型インスリンおよびその使用
JP2014517690A5 (https=)
AU2020243073B2 (en) Recombinant CCN domain proteins and fusion proteins
DK2744831T3 (en) TRANSFERRIN-TUMSTATIN-FUSION PROTEIN AND PROCEDURES FOR PREPARING AND USING THE SAME
CN101914161B (zh) 抑制肿瘤生长的融合蛋白HGFα-Fc及其用途
CA3238005A1 (en) Chimeric antigen receptors
CN115867584A (zh) 用于减少嵌合抗原受体强直信号传导的方法和组合物
WO2022166905A1 (zh) 一种针对hpv的高亲和力tcr
HK40092774A (zh) 使用激活素受体ii型变体的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20140716

RJ01 Rejection of invention patent application after publication